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Abstract 
 
Context:  
Several non-invasive tests have been developed for the diagnosis of bladder outlet obstruction 
(BOO) in men to avoid the burden and morbidity associated with invasive urodynamics. The 
diagnostic accuracy of these tests, however, remain uncertain. 
 
Objective: 
To systematically review the available evidence regarding the diagnostic accuracy of non-
invasive tests in diagnosing BOO in men with lower urinary tract symptoms (LUTS) using 
the pressure-flow study as a reference standard.  
 
Evidence acquisition: 
The EMBASE, MEDLINE, Cochrane Database of Systematic Reviews, Cochrane Central, Google 
Scholar, and WHO International Clinical Trials Registry Platform Search Portal databases were 
searched up to May 18
th
 2016. All studies reporting the diagnostic accuracy of non-invasive tests for 
BOO or DUA in men with LUTS compared to pressure-flow studies were included. Two reviewers 
independently screened all articles, searched the reference lists of retrieved articles, and performed the 
data extraction. The quality of evidence and risk of bias was assessed using the QUADAS-2 tool.  
 
Evidence synthesis: 
The search yielded 2,774 potentially relevant reports. After screening titles and abstracts 53 reports 
were retrieved for full-text screening, of which 42 (recruiting a total of 4444 patients) proved eligible. 
Overall, the results were predominantly based on findings from non-randomised experimental studies 
and, within the limits of such study designs, the quality of evidence was typically moderate across the 
literature. Differences in the non-invasive test BOO threshold values and variations in the urodynamic 
definition of BOO between studies limited the comparability of the data. The detrusor wall thickness 
(median sensitivity 82%, specificity 92%), near-infrared spectroscopy (median sensitivity 85%, 
specificity 87%), and penile cuff test (median sensitivity 88%, specificity 75%) were all found to have 
high sensitivity and specificity in diagnosing BOO. Uroflowmetry with a maximum flow rate of less 
than 10ml/s was reported to have a lower median sensitivity and specificity of 68% and 70%, 
respectively. Intravesical prostatic protrusion of more than 10mm was reported to have a similar 
diagnostic accuracy with a median sensitivity and specificity of 68% and 75%.  
 
Conclusions: 
A number of non-invasive tests have been shown to have a high sensitivity and specificity in the 
diagnosis of BOO in men. However, although the majority of studies have a low overall risk of bias 
the available evidence is limited by heterogeneity. While several tests have shown promising results 
regarding the non-invasive assessment of BOO, invasive urodynamics remain the gold standard. 
 
 
Patient summary: 
Urodynamics is an accurate but potentially uncomfortable test for patients in diagnosing bladder 
problems such as obstruction. We performed a thorough and comprehensive review of the literature to 
determine if there were less uncomfortable but equally effective alternatives to urodynamics for 
diagnosing bladder problems. We found some simple tests which appear promising although they 
were not as accurate. Further research is needed before these tests are routinely used in place of 
urodynamics 
 
 
1 Introduction 
 
Lower urinary tract symptoms (LUTS) are prevalent and bothersome in men and women of all ages. 
Determining whether these symptoms are due to bladder outflow obstruction (BOO) is important in 
determining the optimal management (1). Indeed, the success rate from surgical procedures, such as 
transurethral resection of the prostate, is presumed to be superior in patients with urodynamically 
documented BOO. However, it is not possible to reliably diagnose BOO based on clinical symptoms 
alone, and the gold standard for diagnosis is by urodynamic assessment with a pressure-flow study. 
However, this is an invasive test with risks of bothersome urinary symptoms, haematuria and urinary 
tract infection. Furthermore, it can be unpleasant, with considerable rates of anxiety and 
embarrassment (2). It also requires dedicated equipment and specific expertise, and is expensive. 
Consequently, a number of non-invasive tests have been described to replace the pressure-flow study 
in diagnosing BOO in men with LUTS.  The objective of this systematic review is to determine the 
diagnostic accuracy of non-invasive tests in diagnosing BOO in men with LUTS with reference to the 
gold standard, invasive urodynamics.  
 
2. Evidence acquisition 
 
We used standard methods recommended by the Cochrane Methods Group for the Systematic Review 
of Screening and Diagnostic Tests (3), Preferred Reporting Items for Systematic Reviews (PRISMA), 
and Standards for Reporting Diagnostic Accuracy Studies (STARD)  (4). The study protocol was 
published on PROSPERO (CRD42015019412).  
 
2.1 Search strategy 
 
An experienced research librarian (CY) collaborated in planning the search strategy. The EMBASE, 
MEDLINE, Cochrane Database of Systematic Reviews, Cochrane Central (Cochrane HTA, DARE, 
HEED), Google Scholar, and WHO international Clinical Trials Registry Platform Search Portal 
databases were searched up to May 18
th
 2016. Only English language articles were included and the 
detailed search strategy is described in Appendix 1. Additional sources of articles included the 
reference lists of included studies and clinical content experts (European Association of Urology Male 
LUTS Guideline Panel). Two reviewers (SM and RU) screened all abstracts and full-text articles 
independently. Disagreement was resolved by discussion, and where no agreement was reached, a 
third independent party acted as an arbiter (AKN). 
 
 
2.2 Types of study design included 
 
All types of studies (including at least 10 participants) assessing the diagnostic accuracy of non-
invasive tests using invasive urodynamics as a reference standard were eligible. 
 
2.3 Types of participant included 
Eligible study populations recruited adult men (≥18 years) with LUTS (as defined by the study 
authors). Studies where the proportion of men with either neurological disease or urethral stricture 
was higher than 10% were excluded. 
 
2.4 Types of intervention included 
 
The following non-invasive tests (i.e. index tests) were eligible for inclusion. A detailed description of 
each index test is included in Appendix 2. 
1. Prostate volume/height  
2. Intravesical prostate protrusion (IPP) 
3. Detrusor/bladder wall thickness measured on transabdominal ultrasound (DWT/BWT) 
4. Ultrasound-estimated bladder weight (UEBW) 
5. Doppler ultrasound 
6. Near-infrared spectroscopy (NIRS) 
7. Uroflowmetry 
8. Penile cuff test (PCT) 
9. External condom catheter method 
 
 
2.5 Outcome measures 
 
The primary outcome measures for diagnostic accuracy for predicting BOO were sensitivity, 
specificity, positive predictive value and negative predictive value. Secondary outcome measures 
included test reliability and reproducibility, adverse events, patient satisfaction, and cost effectiveness 
as defined by the trial authors, if reported.  
 
2.6 Assessment of risk of bias 
 
The risk of bias (RoB) in the included studies was assessed using the QUADAS-2 tool (5). It consists 
of 4 domains of patient selection, index test, reference standard, and the flow of patients through the 
study, and timing of the index test and reference standard. RoB was assessed for each domain, and the 
first 3 domains were also assessed for concerns regarding applicability. 
A list of the most important potential confounders for outcomes was developed a priori with clinical 
content experts (EAU Non-neurogenic Male LUTS guideline panel). The confounder assessment 
consisted of whether each prognostic confounder was considered and whether, if necessary, the 
confounder was controlled for in the analysis. The potential confounding factors assessed were: (1) 
whether indices for pressure flow study were determined automatically or manually; (2) whether the 
quality of urodynamic study adhered to contemporaneous quality standards (i.e. International 
Continence Society standards for studies from 2002 onwards; for studies pre-2002, judgement was 
made by the reviewer and panel member). 
2.7 Data analysis 
 
Due to the expected heterogeneity in the definitions, thresholds and technical variations of the 
included index tests, a qualitative (i.e. narrative) synthesis of all included studies was planned.  For 
studies with multiple publications, only the most up-to-date or complete data for each outcome was 
analysed.  
Subgroup analyses were planned for the following groups, if data were available: High vs. low 
prevalence of BPE, men with a high prevalence of detrusor underactivity (DUA), men with storage 
versus voiding LUTS, severity of LUTS, men with previous prostate surgery, men treated with 
medical therapy for storage and/or voiding LUTS, and risk factors for BPE (PSA, Prostate volume, 
post-void residual. 
For each study, the elements of diagnostic accuracy were determined by way of a two-by-two 
contingency table consisting of true positive (TP), false positive (FP), false negative (FN) and true 
negative (TN) based on data reported by authors. If there was discrepancy between the observed data 
(i.e. TP, FP, FN and TN) and derived data (i.e. sensitivity, specificity, positive predictive value and 
negative predictive value), the observed data took priority, and diagnostic accuracy elements were 
calculated from the observed data as reported by authors. In addition, descriptive statistics including 
median and interquartile range, and range, were provided for all diagnostic accuracy elements for 
each type of index test considered as a whole to provide a summary measure across studies. 
Sensitivity analysis was planned for each type of index test using the most commonly used threshold 
values relevant to each test only. 
 
 
3 Evidence synthesis 
 
3.1 Quantity of evidence identified  
The study selection process is outlined in Fig. 1. A total of 42 studies were eligible for inclusion: 41 
non-randomised experimental studies and 1 retrospective comparative study (6-47). 
 
3.2 Characteristics of included studies 
The baseline characteristics of all 42 included studies are shown in Table 1. A total of 4,444 patients 
were recruited.  
 
3.3 Risk of bias assessment 
The summary of methodological quality and RoB assessments is shown in Fig. 2. The majority of 
studies had a low RoB in terms of applicability, with most studies including men that are 
representative of those that would be expected to undergo this test in routine practice. The study by 
Botkor-Rasmussen included a larger proportion of asymptomatic or minimally-symptomatic men 
compared to the other studies, and Sullivan et al. included some normal volunteers, which could 
therefore affect the applicability of the diagnostic test accuracy results obtained (12, 44). Hirayama et 
al. included only men with small prostates (<20ml) which would not be a representative sample of 
those that would receive the test in clinical practice, and Kuo et al. used a definition of BOO on 
urodynamics (PdetQmax >50 cmH2O) that is not widely accepted and therefore may affect the 
accuracy of the results (21, 27).   
The principal source of bias across studies related to the reporting of the reference standard. Although 
the ICS nomogram is now widely accepted to define BOO on voiding cystometry, a number of studies 
used different definitions of BOO which may affect the diagnostic accuracy results obtained. 
Furthermore, some studies classified both equivocal and non-obstructed patients into the same non-
obstructed group which may introduce an element of bias into the overall results (6). In addition to 
this, blinding to the index test and reference standard was either not clearly discussed or was not 
performed in a number of studies, again accounting for an unclear or high RoB in data interpretation 
across studies. In the studies assessing NIRS, the index test and reference standard had to be 
undertaken simultaneously and so this introduces a RoB with the same investigator analysing the 
results of both tests at the same time.  
The overall RoB across most domains was generally low across most studies, although there was 
significant heterogeneity of definitions of thresholds, index tests and reference tests.  
 
3.4 Narrative synthesis of results  
3.4.1 Diagnostic accuracy results 
The individual results for each study, organised according to the index test being assessed, are shown 
in Table 2. The overall results for each type of index test considered are available in Table 3. It was 
not possible to perform subgroup analyses because of lack of data.  
 
3.4.1.1 Penile cuff test 
Seven studies investigated the diagnostic accuracy of the penile cuff test. Overall, diagnostic accuracy 
was high with a median sensitivity and specificity of 88% and 70%, respectively. There was a low 
risk of bias across most studies but significant heterogeneity in the threshold values used to diagnose 
BOO, with 3 studies using the nomogram developed by Griffiths et al. (11, 18, 22), two using 
different nomograms (32, 42), and two using a penile urethral compression-release (PCR) index of 
either 160% or 100% (20, 44). As a result, it is impossible to reliably pool the results of these studies.  
 
3.4.1.2 Uroflowmetry 
Uroflowmetry was assessed in a total of 2,580 patients across 16 studies. Thirteen studies used a cut-
off value of 10ml/s to diagnose BOO and reported a median sensitivity and specificity of 68.3% and 
70.5%, respectively, with a PPV and NPV of 74.3% and 68% (7, 12, 13, 15, 16, 18, 20, 21, 26, 30, 33, 
34, 38, 40, 41). However, studies varied considerably in their choice of defining variable and cut-off 
values. The range of sensitivity and specificity values across studies was so wide that no conclusions 
can be drawn. As would be expected, lowering the cut-off value for Qmax seemed to increase 
sensitivity at the expense of specificity and vice-versa. But baseline symptom severity also acts as a 
significant confounder which we are unable to control for with the available data. Overall the 
diagnostic accuracy of uroflowmetry in diagnosing BOO appears to be relatively limited compared 
with the other index tests.  
 
3.4.1.3 Detrusor or bladder wall thickness (DWT/BWT) 
DWT was studied in 848 patients across 8 studies (6, 8, 16, 17, 24, 31, 33, 34), 5 of which used a cut-
off of 2mm to define BOO with a high median sensitivity and specificity of 82.7% and 92.6%, 
respectively, with a PPV and NPV of 90.5% and 85%, respectively. Furthermore, a well-conducted 
exploratory study reported a cut-off value of 2.9mm as having the best diagnostic value, with a 
specificity of 100%. Altered DWT and BWT may have a multifactorial basis, and further assessments 
in well-designed statistically-powered trials are needed to assess wider application in clinical service 
delivery. 
 
3.4.1.4 Bladder weight (UEBW) 
UEBW was only assessed in 2 studies, both utilising different threshold values to define BOO, and 
both finding a wide variation in diagnostic accuracy (19, 25). Therefore, little inference can be made 
based on the available data on bladder weight. 
 
3.4.1.5 External condom method 
The external condom catheter method was assessed in a single study reporting that up to 73% of 
patients could be correctly diagnosed with the external condom catheter technique (37). However, 
from the limited data available it appears that test failure, for various reasons, is a limiting factor. 
 
3.4.1.6 Intravesical prostatic protrusion (IPP) 
IPP was studied in a total of 1,013 patients across 10 studies (6, 8, 9, 13, 15, 17, 23, 28, 36, 39). Five 
studies used a cut-off of 10mm to define BOO and overall reported a similar diagnostic accuracy to 
uroflowmetry alone with a median sensitivity and specificity of 67.8% and 74.8%, with a PPV and 
NPV of 73.8% and 69.3%. However, threshold values varied, making interpretation difficult.  
 
3.4.1.7 Doppler ultrasound 
Two studies evaluated the role of Doppler ultrasound, one assessing detrusor blood flow and the other 
assessing urinary flow velocity (10, 35). The small patient numbers render the results on Doppler 
ultrasound difficult to interpret with any degree of certainty. 
 
3.4.1.8 Prostate volume and height 
Four studies assessed prostate volume or height, and various threshold values were employed, but all 
of them reported low diagnostic accuracy (16, 17, 28, 45). 
 
3.4.1.9 Near-infrared spectroscopy (NIRS) 
NIRS was assessed in 5 studies, 3 of which used the NIRS algorithm to define BOO (14, 29, 43, 46, 
47). Overall diagnostic accuracy was relatively high with a median sensitivity and specificity of 
85.7% and 87.5%, respectively. The one study using a mathematical modelling and regression tree 
algorithm showed the highest diagnostic accuracy (43). 
 
3.4.2 Results for secondary outcomes 
Secondary outcomes were not addressed due to the lack of data suitable for a critical analysis. 
 
3.5 Discussion 
3.5.1 Principal findings 
A total of 42 studies recruiting a total of 4,444 patients were eligible for inclusion in this SR, which 
assessed the diagnostic accuracy of 9 non-invasive tests. There were significant variations among 
studies investigating the same test, both in terms of the threshold value used to define BOO on the 
non-invasive test as well as the nomograms used to diagnose BOO on invasive urodynamics. For 
studies reporting on most commonly used thresholds to define BOO, the penile cuff test using the 
Griffiths nomogram, DWT > 2mm and the NIRS algorithm had the highest median sensitivities 
ranging from 82-85.7%. These three tests also had the highest median NPV's of 84-89%. The highest 
median PPV's were reported for DWT >2mm and the NIRS algorithm, at approximately 90%. The 
diagnostic accuracy for IPP >10mm was similar to that for a Qmax <10ml/s on free flow rate testing. 
The studies on IPP also appeared to show that specificity increased with increasing IPSS score, a 
confounder that would be controlled for in a good prospective trial. The diagnostic ability of the 
external condom catheter seems promising in the only study included, but this data requires further 
validation in future studies.  
Although the overall RoB was low across many domains for the majority of studies, in many studies, 
the index test and reference standard were performed unblinded, and in some studies the two tests 
were performed simultaneously by the same investigator who also analysed the results obtained. This 
could have potentially biased the interpretation of the findings and final conclusions reached.   
 
3.5.2 Implications for clinical practice 
Pressure-flow studies for the evaluation of men with LUTS are often not performed for practical 
reasons. Several non-invasive techniques have therefore been developed and appear promising in the 
assessment of men with LUTS. From the evidence reviewed in this paper, the penile cuff test, DWT, 
UEBW and NIRS have shown the greatest diagnostic accuracy although further validation in studies 
with more stringent methodological standards are required before they can replace invasive 
urodynamics. Furthermore, there are a number of factors that need to be considered when discussing 
generalisability and delivery costs of these tests. The penile cuff test may cause discomfort or urethral 
bleeding, although this has been reported in only 2% of patients, and technical difficulties have been 
reported to result in exclusion rates of 23% to 46% (48, 49). Similarly, the external condom method 
may also cause discomfort and results may be affected by low flow rates, low voided volumes, and 
abdominal straining (37). Measurement of DWT and UEBW require specific training and there is a 
risk of observer error, and NIRS requires specialised equipment. Doppler ultrasound urodynamics 
suffers from the same limitations of observer error and requires specialised equipment to perform. It is 
clear that these techniques, either alone or in combination, may be used to aid decision-making and 
counselling when evaluating men with LUTS in daily clinical practice, especially if invasive 
urodynamics are unavailable or contra-indicated. However, the quality of the current data is 
insufficient to recommend the routine use of any non-invasive test over pressure-flow studies in 
diagnosing BOO in men with LUTS.  
3.5.3 How the review compares with previous reviews/guidelines 
A number of studies reviewing the evidence for various non-invasive urodynamic tests have been 
published in recent years (50-57). All reviews have reported similar findings to the present review, 
reporting that some non-invasive tests appear promising, especially in combination, but further 
investigation is required before they can replace invasive urodynamics. Importantly, however, the 
methodology in these reviews differ significantly from the present SR. Primarily, this SR is based on 
strict inclusion and exclusion criteria with input from a multidisciplinary expert panel to inform the 
review question. The robust methods used to synthesise the evidence and analyse the data are the 
principal strengths of this study and therefore provide a more accurate evaluation of the available 
evidence compared to the other reviews.  
 
3.5.4 Future research 
This review has demonstrated that several non-invasive tests seem promising in assessing men with 
BOO. However, we have highlighted the limitations of the current evidence base in terms of 
heterogeneity of definitions and threshold values used, and therefore larger studies with more 
stringent methodological standards are required in order to better assess their role in the evaluation of 
men with LUTS. The limitations of existing individual tests have led many investigators to assess the 
role of a combination of tests in improving the diagnostic accuracy for BOO. Although not covered in 
this SR, the role of combining tests is a promising area that requires further assessment.   
3.5.5 Strengths and Limitations 
The strengths of this review are the systematic, transparent, and effective approach taken to examine 
the evidence base, including the use of Cochrane review methodology, the assessment of RoB using 
QUADAS-2, and adherence to PRISMA and STARD guidelines. The clinical question was prioritised 
by a multidisciplinary panel of clinical experts, methodologists and patient representative  (EAU Non-
neurogenic Male LUTS Guideline Panel), and the work was undertaken as part of the panel’s clinical 
practice guideline update for 2016. In addition, the review elements including characteristics of 
participants, index and reference tests, definitions and thresholds were developed a priori in 
conjunction with the panel. The search strategy was complemented by additional sources for 
potentially important articles, including reference lists of included studies and studies identified by the 
expert panel. This approach ensured a comprehensive review of the literature while maintaining 
methodological rigour and enabled the authors to put into clinical context the relevance and 
implications of the review findings.  Moreover, the vast majority of studies were prospective in 
nature, with well-defined index and reference tests, and the overall RoB was generally low across 
studies. The primary limitation was the large heterogeneity among studies, with regard to definitions 
of index tests and reference standards. Furthermore, due to lack of data we were unable to perform 
any subgroup analyses. Another limitation is the basic assumption that invasive urodynamics is a 
definitive diagnostic investigation for BOO in men. It is known that results of invasive urodynamics 
and the nomograms based upon pressure-flow studies can have significant inter and intra-investigator 
variability as well as test-retest variation (58, 59). However, in the absence of a more accurate gold-
standard, all studies on these diagnostic tests will continue to be compared to invasive urodynamics.   
 
4 Conclusion 
 
This study has systematically reviewed the evidence assessing the diagnostic accuracy of non-
invasive tests in diagnosing BOO in men with LUTS using effective methods of evidence acquisition 
and synthesis, with input from a multidisciplinary expert panel to inform the review question and 
review elements. The findings and clinical relevance were interpreted with appropriate clinical 
context provided by the expert panel. Overall, a number of non-invasive tests appear promising with a 
low RoB across most domains for the great majority of studies. Limitations of the current evidence 
base include heterogeneity of definitions and thresholds in regard to index tests and reference 
standards, and therefore this review has highlighted the need for larger prospective studies with better 
methodological quality. In spite of these limitations, the findings from this review can help to provide 
clinical guidance on the accuracy of these tests in daily practice. Therefore, while several tests have 
shown promising results regarding the non-invasive assessment of BOO, pressure-flow study remains 
the gold standard test in determining BOO.  
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Appendix 1: Literature Search Strategy 
The following databases were searched using the provided search strategy: 
Database: EBM Reviews - Cochrane Central Register of Controlled Trials <April 2016>, EBM Reviews - 
Cochrane Database of Systematic Reviews <2005 to May 18, 2016>, Ovid MEDLINE(R) In-Process & Other 
Non-Indexed Citations and Ovid MEDLINE(R) <1946 to Present>, Embase <1974 to 2016 May 18> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp bladder neck stenosis/ or exp Urinary Bladder Neck Obstruction/  
2     exp bladder obstruction/  
3     (bladder adj2 (neck sclerosis or outflow obstruction or outlet obstruction or obstructed 
voiding)).tw,kw.  
4     exp prostate hypertrophy/ or exp Prostatic Hyperplasia/  
5     (benign prostatic hyperplasia or BPH or benign prostatic obstruction or BPO or benign prostatic 
enlargement or BPE or BOO or prostate hypertrophy).tw,kw.  
6     (((detrusor or bladder) adj2 (underactivit* or failure or acontractile or hypocontract*)) or 
DUA).tw,kw.  
7     or/1-6 
8     (pressure adj2 flow).tw,kw.  
9     exp urodynamics/  
10     exp cystometry/ or flow Cytometry/  
11     (urodynamic* or cystometrogram or cystometr* or cystometrography or cystomanometry).tw,kw.  
12     exp bladder pressure/  
13     (detrusor pressure or bladder pressure).tw,kw.  
14     or/8-13  
15     exp non invasive measurement/  
16     (non invasive adj2 (test or measurement)).tw.  
17     (videourodynamics or Video urodynamics).tw,kw.  
18     (uroflowmetry or Urine flowmetry or urine flow measurement or intraureteral flow 
measurement).tw. 
19     ((Penile cuff or UroCuff or free flow rate) adj3 (test or study)).tw.  
20     (Bladder wall thickness or detrusor wall thickness or Bladder weight).tw.  
21     (Condom method or Presumed circle area ratio or Intravesical prostatic protrusion).tw.  
22     exp uroflowmetry/  
23     exp urine flow rate/  
24     or/15-23  
25     7 and 14  
26     7 and 24  
27     25 or 26  
28     exp Lower Urinary Tract Symptoms/  
29     (((lower urinary tract or bladder or urethra* or LUT) adj3 (symptom* or complain*)) or LUTS).tw.  
30     28 or 29  
31     27 and 30  
32     (exp animals/ not humans/) or ((rats or mice or mouse or cats or dogs or in vitro or cell lines) not 
(human* or men or women)).ti.  
33     31 not 32  
34     (children/ not adult/) or ((children or pediatric* or paediatric*) not (aged or adult* or men or 
women)).ti.  
35     33 not 34  
36     women/ not (men/ or (men or male).mp.)  
37     35 not 36  
38     (case report/ or case reports/) not (case series or cases).ti,ab.  
39     37 not 38  
40     note/ or editorial/ or Comment/ or news/  
41     39 not 40  
42     remove duplicates from 41  
 
Appendix 2: Detailed description of non-invasive tests included in this review 
1. Penile cuff test  
 
This test involves the placement of a pneumatic cuff around the penile shaft which is inflated on 
voiding, thereby interrupting flow. The pressure of the resultant fluid column in the urethra is 
estimated to be intravesical pressure and can be used as a measure of bladder contractility (18).   
 
2. Uroflowmetry 
 
The patient is asked to urinate into a container which measures the rate and volume of urine voided, 
and the post-void residual urine volume is then measured with ultrasound. This enables the calculation 
of the maximum flow rate (Qmax) in ml/s and the flow time, as well as allowing assessment of the 
patter of flow (60).  
 
3. Detrusor/bladder wall thickness measured on transabdominal ultrasound 
 
These tests involve measuring the thickness of the detrusor muscle or entire bladder wall using 
transabdominal ultrasound. They are based on the findings from animal models and morphological 
studies that BOO results in detrusor muscle hypertrophy (61, 62), leading to increased BWT and 
DWT.  
 
4. Bladder weight 
 
The measurement of ultrasound-estimated bladder weight (UEBW) is based on the same principle as 
that for BWT or DWT, with bladder weight acting as a measure of detrusor hypertrophy (19).  
 
5. External condom catheter method 
 
The condom method is another way by which isovolumetric bladder pressure can be measured, and is 
based on the same principle as the penile cuff tests. The test involves voiding through a condom 
catheter attached to a valve, and at maximum flow the catheter is occluded and isovolumetric pressure 
measured via a side-port on the valve (63, 64).  
 
6. Intravesical prostate protrusion 
 
The intravesical prostatic protrusion (IPP) is a transabdominal ultrasound-derived measure of prostatic 
configuration, based on the theory that the prostate protrudes into the bladder as it grows, and 
therefore leads to BOO as a result of a ball-valve effect (65).   
 
7. Doppler ultrasound 
 
This involves the use of Doppler ultrasound to measure detrusor blood flow or velocity of urine flow. 
It is based on the principle that detrusor blood flow is reduced in patients with BOO and that 
measuring the detrusor arterial resistive index may be able to predict BOO. Furthermore, by 
measuring the urinary flow velocity in different parts of the urethra, the velocity ratio can be 
calculated and may be used to diagnose BOO (10). 
 
 
8. Prostate volume/height 
 
This is a transabdominal ultrasound-based measurement of the prostatic configuration.    
 
 
9. Near-infrared spectroscopy (NIRS) 
 
This technique involves the measurement of changes in the concentration of oxyhaemoglobin and 
deoxyhaemoglobin (chromophores) in tissue. It is based on the hypothesis that BOO is associated 
with a reduction in detrusor blood flow and oxyheamoglobin levels due to the increased work of the 
detrusor muscle. Consequently, BOO would result in a downward NIRS pattern of slope changes in 
chromophore concentration whereas an unobstructed system would lead to an upward slope (57).  
 
 
Table 1. Baseline characteristics of included studies  
Author and year of 
publication 
 
No. of 
patients Study design 
Index test 
 
Reference standard 
definition of BOO 
 Index test Threshold value Blinding 
 
Abdel-Aal et al. 
2011 
 Non-
randomised 
experimental 
DWT 2mm 
Yes BOOI >40 85 IPP 8mm 
 Combination IPP + DWT 8mm + 2mm 
Aganovic 
2004 
 
Non-
randomised 
experimental 
Uroflowmetry 10ml/s NR 
LPURR>2 
 LPURR>3 
102 LPURR>2 + URA>29 
 Qmax<15 and pDetQmax 
>50 
Aganovic et al. (a) 
2012 
111 Non-
randomised 
experimental 
IPP 10mm 
NR BOOI >40 
BWT 5mm 
Aganovic at el. (b) 
2012 
 
Non-
randomised 
experimental 
IPP 12mm 
NR 
BOOI >40 
 BOON -27.2 BOOI >40 
112 BOON -27.2 URA>29 
 Combination IPP + BOON 10mm, -30 BOOI >40 
 BOON2 -47.4 URA>29 
 BOON2 -50 URA>29 
Belenky et al.  
2003 
29 Non-
randomised 
experimental 
Doppler Ultrasound RI T>0.05 Yes BOOI >40 
Bianchi et al. 
2014 
48 Non-
randomised 
experimental 
PCT 
Griffiths 
nomogram 
No BOOI >40 
Botkor-Rasmussen et al.  
1999 
29 Non-
randomised 
Uroflowmetry 10ml/s No BOOI >40 
Table
experimental 
Chia et al.  
2003 
200 Non-
randomised 
experimental 
Uroflowmetry 10ml/s 
Yes BOOI >40 
IPP 10mm 
Chung et al. 
2010 
33 
Non-
randomised 
experimental 
NIRS pattern on free flow 
Downward 
pattern 
No BOOI >40 
NIRS pattern on pressure-flow 
studies 
Downward 
pattern 
Dicuio et al. 
2005 
25 Non-
randomised 
experimental 
IPP 10mm No DAMPF score 
ElSaied et al. 
2013 
50 Non-
randomised 
experimental 
DWT 2mm   
Yes BOOI >40 Uroflowmetry 10ml/s 
Prostate volume 25ml 
Franco et al. 
2010 
 
Non-
randomised 
experimental 
IPP 12mm 
Yes BOOI >40 
100 DWT 6mm 
 Prostate height 40mm 
 Prostate volume 38ml 
Griffiths et al. 
2005 
144 Non-
randomised 
experimental 
PCT 
Griffiths 
nomogram No BOOI >40 
Uroflowmetry 10ml/s 
Han et al.  
2011 
193 Non-
randomised 
experimental 
Corrected UEBW (UEBW/BSA) 27.86gm NR BOOI >40 
Harding et al.  
2004 
101 Non-
randomised 
experimental 
PCT PCR index 160% 
Yes BOOI >40 
Uroflowmetry 10ml/s 
Hirayama et al.  
2002 
36 Non-
randomised 
experimental 
Uroflowmetry 10ml/s NR BOOI >40 
Kazemeyni et al. 51 Non- PCT Griffiths NR BOOI >40 
2015 randomised 
experimental 
nomogram 
Keqin et al.  
2007 
206 
Retrospective  IPP 8.5 NR BOOI >40 
Kessler et al.  
2006 
 
Non-
randomised 
experimental 
DWT 
1.5mm 
No BOOI >40 
102 2mm 
 2.5mm 
 2.9mm 
Kojima et al. 
1997 
65 Non-
randomised 
experimental 
UEBW 35gm No BOOI >40 
Ku et al. 
2009 
 
Non-
randomised 
experimental 
Uroflowmetry 
10ml/s 
No BOOI >40 
 12ml/s 
212 15ml/s 
 
Residual fraction 
10% 
 20% 
 30% 
Kuo et al. 
1999 
324 Non-
randomised 
experimental 
Uroflowmetry 10ml/s No 
Pdet Qmax >50 used to 
define BOO 
Lim et al. 
2006 
95 Non-
randomised 
experimental 
IPP 10mm 
NR BOOI >40  
Prostate volume 40ml 
Macnab et al. 
2008 
55 Non-
randomised 
experimental 
NIRS NIRS algorithm No Not defined 
Madersbacher et al. 
1997 
253 Non-
randomised 
experimental 
Uroflowmetry 5ml/s No LinPURR>2 
Manieri et al. 
1998 
170 Non-
randomised 
BWT 5mm Yes URA>29 
experimental 
Matulewicz et al. 
2015 
19 Non-
randomised 
experimental 
PCT 
Modified ICS 
nomogram 
No NR 
 Oelke et al. 
2002 
70 Non-
randomised 
experimental 
DWT 2mm 
NR CHESS  
Uroflowmetry 15ml/s 
Oelke et al. 
2007 
160 Non-
randomised 
experimental 
DWT 2mm 
Yes BOOI >40  Uroflowmetry 10ml/s 
 Uroflowmetry 15ml/s 
Ozawa et al. 
2000 
22 Non-
randomised 
experimental 
Doppler Ultrasound VR >1.6 NR BOOI >40 
Pascual et al. 
2011 
39 Non-
randomised 
experimental 
MLL 10.5mm No BOOI >40 
Pel et al. 
2002 
56 Non-
randomised 
experimental 
External condom catheter Qmax/PextMax No BOOI >40 
Poulsen et al. 
1994 
153 Non-
randomised 
experimental 
Uroflowmetry 10ml/s No BOOI >40 
Reis et al. 
2008 
42 Non-
randomised 
experimental 
IPP 
10mm 
Yes BOOI >40 
5mm 
Reynard et al. 
1996 
148 Non-
randomised 
experimental 
Uroflowmetry 10ml/s 1st void 
No BOOI >40  
Uroflowmetry - multiple 10ml/s 4th void 
Reynard et al.  
1998 
897 Non-
randomised 
experimental 
Uroflowmetry 10ml/s No Shafer nomogram 
Salinas et al. 93 Non- PCT Nomogram Yes BOOI >40 
2003 randomised 
experimental 
described  
Stothers et al. 
2010 
64 Non-
randomised 
experimental 
NIRS CART model No BOOI >40 
Sullivan et al. 
2000 
90 
Non-
randomised 
experimental 
Penile compression release PCR 100% NR 
outlet obstruction was 
defined as a voiding 
profilometry 
gradient across the bladder 
neck and prostatic urethra of 
>5 cm H2O in the absence 
of distal obstruction. 
Watanabe et al. 
2002 
51 Non-
randomised 
experimental 
Prostate volume and H:W 30ml and 0.8 No LinPURR ≥3 
Yurt et al. 
2012 
53 Non-
randomised 
experimental 
NIRS NIRS algorithm No BOOI >40 
Zhang et al. 
2013 
87 Non-
randomised 
experimental 
NIRS NIRS algorithm 
Yes BOOI >40  
uroflowmetry + PVR 
10ml/s and 
100ml 
 
Table 1: Baseline characteristics of included studies 
Key: BOOI = Bladder outflow obstruction index, BOON = bladder outflow obstruction number, BWT = bladder wall thickness, CART = classification and 
regression tree, DWT = detrusor wall thickness, DAMPF = detrusor-adjusted mean PURR factor, LPURR = linear passive urethral resistance relation, NIRS = 
near-infrared spectroscopy, NR = not reported, NPV = negative predictive value, PCR = penile compression ratio, PPV = positive predictive value, RI = 
resistive index, UEBW = ultrasound-estimated bladder weight, URA = urethral resistance algorithm, VR = velocity ratio 
 
Table 2. Summary of results for all index tests 
Key: BOOI = Bladder outflow obstruction index, BWT = bladder wall thickness, CART = classification and regression tree, DWT = detrusor wall thickness, 
DAMPF = detrusor-adjusted mean PURR = factor, DAN-PSS = Danish prostatic symptom score, IPSS = International prostate symptom score, LPURR = linear 
passive urethral resistance relation, NIRS = near-infrared spectroscopy, NR = not reported, NPV = negative predictive value, PCR = penile compression ratio, 
PPV = positive predictive value, RI = resistive index, UEBW = ultrasound-estimated bladder weight, URA = urethral resistance algorithm, VR = velocity ratio  
Penile Cuff test 
Study  
Threshold 
value 
Reference standard 
definition of BOO 
Mean 
age 
(range) 
Mean 
IPSS 
(range) 
Prevalence 
of BOO  
(%) 
Sensitivity Specificity PPV NPV 
Bianchi et al. 
2014 
Griffiths 
nomogram 
BOOI >40 61.5 NR 
44 
100 63 67.7 100 
Griffiths et 
al. 2005 
Griffiths 
nomogram 
BOOI >40 NR NR 
39 
64 81 68 78 
Kazemeyni 
et al. 2015 
Griffiths 
nomogram 
BOOI>40 66.5 NR 
35 88.89 75.7 66.7 93 
Harding et 
al. 2004 
PCR index 
160% 
BOOI >40 
63 (20-
88) 
NR 
28 
78 84 69 NR 
Matulewicz 
et al. 2015 
Modified ICS 
nomogram 
NR NR 
16 (6-
30) 
NR 75 66 92 
NR 
Salinas et al. 
2003 
Nomogram 
described in 
paper 
BOOI >40 54.1 NR 
28 
100 55.6 71.4 100 
Sullivan et 
al. 2000 
PCR 100% 
outlet obstruction was 
defined as a voiding 
profilometry gradient 
across the bladder neck 
and prostatic urethra of >5 
cm H2O in the absence 
of distal obstruction. 
NR NR 
48 
90.7 70.2 73.6 89.2 
 
Uroflowmetry 
Study 
Threshold 
value 
Reference 
standard 
definition of 
BOO 
Mean age, yr 
 
Mean IPSS 
(range) 
Prevalence 
of BOO  
(%) 
Sensitivity Specificity PPV NPV 
Aganovic 2004 10ml/s 
LPURR>2 
64.68 14.48 
 63 88 94 42 
LPURR>3  72 69 69 72 
LPURR>2 + 
URA>29 
63 
72 92 94 68 
Qmax<15 and 
pDetQmax >50 
 
67 45 50 63 
Botkor-
Rasmussen et 
al. 1999 
10ml/s BOOI >40 
Median 66 
(51-85) 
DAN-PSS 4 
52 
33 100 100 58 
Chia et al. 
2003  
10ml/s BOOI >40 64.6 (50-94) 20.3 
63 
90 48 74 75 
Dicuio et al. 
2005 
10ml/s DAMPF score 67.9 (47-86) 22.4 (6 - 35) 
64 
NR NR 100 NR 
ElSaied et al. 
2013 
10ml/s BOOI >40 61.7 (53-76) 13.4 (4 - 22) 
46 
100 37 57.5 100 
Griffiths et al. 
2005 
10ml/s BOOI >40 NR NR 
39 
59 89 77 77 
Harding et al. 
2004 
10ml/s BOOI >40 63 (20-88) NR 
28 
81 64 51 
 
Hirayama et 
al. 2002 
10ml/s BOOI >40 67.7 (50-83) 17.1 (9 - 33) 
60 
NR NR 65 NR 
Ku et al. 2009 
10ml/s 
BOOI >40 
Median 68 
(44-89 
18.1 (no BOO), 
19.7 (BOO) 
 
27 
57.9 65.8 38.4 81 
12ml/s 77.2 54.2 38.3 86.6 
15ml/s 94.7 27.7 32.5 93.5 
Madersbacher 
et al. 1997 
5ml/s LinPURR>2 66.5 (53-81) 16 
53 
16 96 85.1 46.9 
Oelke et al. 
2002 
15ml/s CHESS 63 (42-82) 14.4 (2 - 29) 
47 
100 25 55 100 
Oelke et al. 
2007 
15ml/s 
BOOI >40 
62 (40-89) 
(Median) 
15 (2 - 30) 
(Median) 
47 99 39 59 97 
10ml/s  68 73 69 72 
Poulsen et al. 
1994 
10ml/s 
BOOI >40 68 (32-90) 
DAN-PSS 10 (No 
BOO), 11 (BOO) 
65 68.7 57.4 74.7 50 
15ml/s 89.9 31.5 70.6 62.9 
Reynard et al. 
1998 
10ml/s Shafer 
nomogram 
66.5 (45-88) NR 
60 47 70 70 46.5 
15ml/s  82 38 67 57.6 
Reynard et al. 
1996 
10ml/s 
1st void 
BOOI >40 NR NR 
 
61 
71 71 79 61 
10ml/s 
4th void 
29 96 93 47 
 
 
 
 
 
 
 
 
 
 
 
Detrusor and bladder wall thickness 
Study 
Index 
test 
Threshold 
value 
Reference 
standard 
definition of BOO 
Mean 
age, yr 
Mean IPSS 
(range) 
Prevalence 
of BOO  
(%) 
Sensitivity Specificity PPV NPV 
Abdel-Aal et al. 
2011 
DWT 2mm BOOI >40 
58.7 (50-
72) 
12.45 (6.5 - 
25) 
30 
65.7 76 65.7 76 
ElSaied et al. 
2013 
DWT 2mm BOOI >40 
61.7 (53-
76) 
13.4 (4 - 22) 
46 
82.7 92.6 90.5 86.2 
Franco et al. 
2010 
DWT 6mm BOOI >40 
67 (48-
80) 
15 (9 - 25) 
76 
73 82 90 50 
Kessler et al. 
2006 
DWT 
1.5mm 
BOOI >40 
67 (59-
77) 
(Median) 
17 (no BOO), 
22 (BOO) 
(median) 
 
 
60 
100 15 64 100 
2mm 92 68 81 85 
2.5mm 69 88 89 65 
2.9mm 43 100 100 54 
Oelke et al. 
2002 
DWT 2mm CHESS 
63 (42-
82) 
14.4 (2 - 29) 
47 
63.6 97.3 95.5 75 
Oelke et al. 
2007 
DWT 2mm BOOI >40 
62 (40-
89) 
(Median) 
15 (2 - 30) 
(Median) 
47 
83 95 94 86 
Aganovic et al. 
(a) 2012 
BWT 5mm BOOI >40 
65.4 (48-
82) 
18.2 (6 - 31) 
49 
64.5 59.2 NR NR 
Manieri et al. 
1998 
BWT 5mm URA>29 
64.5 (34-
88) 
14.91 (0-29) 
57 
55.4 91 87.9 63.4 
 
 
 
 
 
  
Bladder weight 
Study Index test 
Threshold 
value 
Reference 
standard 
definition of BOO 
Mean 
age, yr 
Mean 
IPSS 
(range) 
Prevalence 
of BOO  (%) Sensitivity Specificity PPV NPV 
Han et 
al. 2011 
Corrected UEBW 
(UEBW/BSA) 
27.86gm BOOI >40 63.5 19.9 
26 
61.9 59.8 33.8 82.6 
Kojima 
et al. 
1997 
UEBW 35gm BOOI >40 
71 (45-
89) 
NR 
52 
85.3 87.1 87.9 84.4 
 
 
 
 
 
 
 
 
 
 
 External condom method 
Study 
Threshold 
value 
Reference 
standard 
definition 
of BOO 
Mean age, 
yr 
Mean 
IPSS 
(range) 
Prevalence 
of BOO  
(%) 
Sensitivity Specificity PPV NPV Comments 
Pel et 
al. 
2002 
Qmax/Pext
Max 
BOOI >40 
62 (no 
BOO), 51 
(equivocal), 
62 (BOO) 
NR 
 
       29 
90.9 92.3 96.7 80 
This is in the 46 out of 75 patients 
(61.3%) who were able to 
successfully perform the non-
invasive test 
 
 
 
 
 
 
 
 
 
 
 
 
 Intravesical prostatic protrusion 
Study 
Threshold 
value 
Reference standard 
definition of BOO 
Mean age, 
yr 
Mean IPSS 
(range) 
Prevalence 
of BOO  (%) Sensitivity Specificity PPV NPV 
Aganovic et 
al. (a) 2012 
10mm BOOI >40 
65.4 (48-
82) 
18.2 (6 - 31) 
49 
59.6 81.4 73.8 69.6 
Chia et al. 
2003 
10mm BOOI >40 
64.6 (50-
94) 
20.3 
63 
76 92 94 69 
Dicuio et al. 
2005 
10mm DAMPF score 
67.9 (47-
86) 
22.4 (6 - 35) 
64 
NR NR 100 NR 
Lim et al. 
2006 
10mm BOOI >40 
66 (52-88) 
(Median) 
12 (1-32) 
(Median) 
49 
46 65 72 46 
Reis et al. 
2008 
10mm BOOI >40 64 (56-73) 13 (6 - 20) 
48 
80 68.2 69.6 78.9 
Abdel-Aal et 
al. 2011 
8mm BOOI >40 
58.65 (50-
72) 
12.45 (6.5 - 25) 
30 
80 80 73.7 85.1 
Aganovic et 
al. (b) 2012 
12mm BOOI >40 
65.3 (48-
80) 
18.2 (6 - 31) 
NR 
59.6 81.3 73.8 69.6 
Franco et al. 
2010 
12mm BOOI >40 67 (48-80) 15 (9 - 25) 
76 
65 77 88 47 
Keqin et al. 
2007 
8.5mm BOOI >40 71 (55-84) 
16.8 ( grade 1-2 
IPP) v 18.6 
(grade 3 IPP) 
NR 
75 82.6 NR NR 
Pascual et al. 
2011 
10.5mm BOOI >40 
61.6 (BOO), 
64.7 (No 
BOO) 
14.7 (BOO)  13.7 
(no BOO) 
54 
90.5 72.2 76 85 
Reis et al. 
2008 
5mm BOOI >40 64 (56-73) 13 (6 - 20) 
48 
95 50 63.3 91.7 
 
 
 Doppler ultrasound 
Study 
Threshold 
value 
Reference 
standard 
definition of 
BOO 
Mean age, yr 
Mean IPSS 
(range) 
Prevalence 
of BOO  (%) 
Sensitivity Specificity PPV NPV 
Belenky et 
al. 2003 
RI T>0.05 BOOI >40 65.6 (46-76) NR 
75 
NR NR 95 57 
Ozawa et 
al. 2000 
VR >1.6 BOOI >40 NR NR 
60 
NR NR 100 NR 
 
 
 
 
 
 
 
 
 
 
 
 Prostate volume or height 
Study Index test 
Threshold 
value 
Reference 
standard 
definition of 
BOO 
Mean 
age, yr 
Mean IPSS 
(range) 
Prevalence 
of BOO  
(%) Sensitivity Specificity PPV NPV 
ElSaied et 
al. 2013 
Prostate volume 25ml BOOI >40 
61.7 (53-
76) 
13.4 (4 - 22) 
46 
87 29.6 51.3 72.7 
Franco et 
al. 2010 
Prostate height 40mm 
BOOI >40 
67 (48-
80) 
16 (9 - 25) 
76 68 54 82 48 
Prostate volume 38ml 72 61 84 44 
Lim et al. 
2006 
Prostate volume 40ml BOOI >40 
66 (52-
88) 
(Median) 
12 (1-32) 
(Median) 
49 
51 38 65 42 
Watanabe 
et al. 2002 
Prostate volume 
and H:W 
30ml and 
0.8 
LinPURR ≥3 
66.4 (49-
84) 
NR 
47 
42 100 NR NR 
 
 
 
 
 
 
 
 
 
  
Near infrared spectroscopy 
Study 
Threshold 
value 
Reference 
standard 
definition of 
BOO 
Mean age, 
yr 
Mean IPSS 
(range) 
Prevalence 
of BOO  (%) 
Sensitivity Specificity PPV NPV 
Macnab 
et al. 
2008 
NIRS 
algorithm 
Not defined 
67.3 (50-
91) (BOO), 
56.8 (40-
77) (no 
BOO) 
20.2 (no 
BOO), 19.6 
(BOO) 
49 
85.71 88.89 88.89 85.71 
Yurt et al. 
2012 
NIRS 
algorithm 
BOOI >40 58.8 17.8 
55 
86 87.5 89.2 84 
Zhang et 
al. 2013 
NIRS 
algorithm 
BOOI >40 
68.5 (56-
85) 
NR 
72 
68.3 62.5 82.7 42.9 
Chung et 
al. 2010 
Downward 
pattern on 
free flow 
BOOI >40 67 19 
79 
34.6 42.9 69.2 15 
Chung et 
al. 2010 
Downward 
pattern on 
pressure-
flow study 
BOOI >40 NR NR 
79 
61.1 40 78.6 22.2 
Stothers 
et al. 
2010 
CART model BOOI >40 62 (49-91) 19 (12-34) 
47 
100 87.5 93.8 100 
  
Table 3 (a). Summary of results for each type of index test (grouped) 
Test 
No. of 
studies 
No. of 
patients 
Median 
sensitivity (IQR) 
Sensitivity 
range 
Median 
specificity (IQR) 
Specificity 
range 
Median 
PPV 
PPV 
range 
Median 
NPV 
NPV 
range 
Penile Cuff test 7 546 
88.89 (76.5-
95.3) 
64 - 100 70.2 (64.5-78.3) 55.6 - 84 
69 (67.9 
- 72.5) 
66.7 - 
92 
93 (89.2-
100) 
78 - 100 
Uroflowmetry 16 2580 72 (58.4 - 89.9) 16 - 100 64 (38.5 -81) 25 - 100 
70 (57.5 
- 79) 
32.5 - 
100 
70 (57.7 - 
85.2) 
46.5 - 100 
Detrusor wall 
thickness 
8 848 69 (64-82.8) 43 - 100 88 (72-93.8) 15 - 100 
89.5 
(82.7-
93.1) 
64 - 100 
75.5 
(63.8-
85.7) 
50 - 100 
Bladder weight 2 258 73.6 61.9 - 85.3 73.45 59.8 -  87.1 60.85 
33.8 - 
87.9 
83.5 
82.6 - 
84.4 
External condom 
catheter 
1 56 90.9 
 
92.3 
 
96.7 
 
80 
 
Intravesical 
prostatic 
protrusion 
10 1013 75.5 (60.9-80) 46 - 95 78.5 (69.2-81.3) 50 - 92 
73.8 
(72.4-
85) 
69.6 - 
100 
69.6 (69 - 
85) 
46 - 85.1 
Doppler 
ultrasound 
2 51 No data No data No data No data 
97.5 
(96.2-
98.7) 
95 - 100 57 No data 
Prostate volume 3 245 72 (61.5-79.5) 51 - 87 38 (33.8-49.5) 29.6 - 61 
65 
(58.1-
74.5) 
51.3 - 
84 
44 (43-
58.3) 
42 - 72.7 
NIRS 5 282 85.71 (68.3-86) 61.1 - 100 87.5 (62.5-87.5) 40 - 87.5 
88.89 
(82.7-
89.2) 
78.6 - 
93.8 
84 (42.9-
85.71) 
22.2 - 100 
 
 
 
  
Table 3 (b). Summary of results for each type of index test using the most commonly used threshold values relevant to each test (grouped) 
Test 
Threshold 
value 
No. of 
studies 
No. of 
patients 
Median 
sensitivity 
(IQR) 
Range 
Median 
specificity 
(IQR) 
Range 
Median 
PPV 
(IQR) 
Range 
Median 
NPV 
(IQR) 
Range 
Penile Cuff test 
Griffiths 
nomogram 
3 243 
88.9 (76.4-
94.4) 
64 - 100 
75.7 (69.3 
- 78.3) 
63 - 81 
67.7 
(67.2 - 
67.9) 
66.7 - 68 
93 (85.5 
- 96.5) 
78 - 100 
Uroflowmetry 10ml/s 13 2257 
68.3 (55.1 -
74.2) 
29 - 100 
70.5 (62.3 
-89.7) 
37 - 100 
74.3 
(66-
89.5) 
38.4 - 100 
68 (54-
76) 
46.5 - 100 
Detrusor wall 
thickness 
2mm 5 467 
82.7 (65.7-
83) 
63.6 - 92 
92.6 (76-
95) 
68 - 97.3 
90.5 
(81-94) 
65.7 - 95.5 
85 (76-
86) 
75 - 86.2 
Intravesical 
prostatic 
protrusion 
10mm 5 473 
67.8 (56.2-
77) 
46 - 80 
74.8 
(67.4-84) 
65 - 92 
73.8 
(72-94) 
69.6 - 94 
69.3 
(63.2-
71.9) 
46 - 78.9 
NIRS 
NIRS 
algorithm 
3 195 
85.71 (77-
85.8) 
68.3 - 86 
87.5 (75-
88.1) 
62.5 - 
88.9 
88.89 
(85.7-
89) 
82.7 - 89.2 
84 
(63.4-
84.8) 
42.9 - 
85.71 
 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097 
 
For more information, visit www.prisma-statement.org. 
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Additional records identified 
through other sources 
(n = 16) 
Records after duplicates removed 
(n = 2772) 
Records screened 
(n = 2772) 
Records excluded 
(n = 2719) 
Full-text articles assessed 
for eligibility 
(n = 53) 
Full-text articles excluded  
(n = 11) 
 
Review articles - 3 
Insufficient data - 8 
  
Studies included in 
qualitative synthesis 
(n = 42) 
Illustration

Take home message 
A number of non-invasive tests have been studied for the diagnosis of BOO in men with 
LUTS and found to have a high sensitivity and specificity but high heterogeneity. Despite 
these promising results of the non-invasive assessment of BOO, pressure-flow study remains 
the gold standard test. 
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